ChemBriefNovo-backed Windward Bio Targets $1 Billion Valuation in US IPO
Swiss drug developer Windward Bio Group targets a $1 billion valuation in its US IPO, raising $185.3 million for antibody medicines treating respiratory and dermatologic diseases. The offering is back
reuters · 2026-11-09 04:09